Filing Details

Accession Number:
0001104659-25-016122
Form Type:
13G Filing
Publication Date:
2025-02-20 19:00:00
Filed By:
Partner Fund Management
Company:
Pmv Pharmaceuticals Inc. (NASDAQ:PMVP)
Filing Date:
2025-02-21
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Beneficially Owned Number of Shares Beneficially Owned Number of Aggregate Shares Percent of Class
PFM Health Sciences, LP 0 2,598,827 5.0%
PFM Health Sciences GP, LLC 0 2,598,827 5.0%
Partner Asset Management, LLC 0 2,598,827 5.0%
Brian D. Grossman 0 2,598,827 5.0%
Filing





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G



Comment for Type of Reporting Person:  The percentages reported in this Schedule 13G are based upon 51,747,130 Shares outstanding as of November 6, 2024 (according to the issuer's Form 10-Q as filed with the Securities and Exchange Commission on November 7, 2024).


SCHEDULE 13G




SCHEDULE 13G




SCHEDULE 13G




SCHEDULE 13G


 
PFM Health Sciences, LP
 
Signature:/s/ Darren Mooney
Name/Title:Darren Mooney, Authorized Signatory
Date:02/21/2025
 
PFM Health Sciences GP, LLC
 
Signature:/s/ Darren Mooney
Name/Title:Darren Mooney, Authorized Signatory
Date:02/21/2025
 
Partner Asset Management, LLC
 
Signature:/s/ Darren Mooney
Name/Title:Darren Mooney, Authorized Signatory
Date:02/21/2025
 
Brian D. Grossman
 
Signature:/s/ Darren Mooney
Name/Title:Darren Mooney, attorney-in-fact*
Date:02/21/2025

Comments accompanying signature:  * Darren Mooney is signing on behalf of Brian Grossman as attorney-in-fact pursuant to a power of attorney dated February 1, 2024, and incorporated by reference herein. The power of attorney was filed as an attachment to a filing by certain of the Reporting Persons on Schedule 13G/A for Praxis Precision Medicines, Inc. on February 14, 2024.
Exhibit Information

Exhibit 99.1 - Joint Filing Agreement